Fitzgerald Kevin Joseph

CSO & EVP, Head of ResearchALNYLAM PHARMACEUTICALS, INC. (ALNY) · full profile →Form 4 · filed Mar 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.1M
Net Open-Market Flow
-$1.1M
Transactions
16
15 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 3, 2026Sell(S)289$316.55$91K23K
Mar 3, 2026Sell(S)282$318.62$90K23K
Mar 3, 2026Sell(S)722$320.51$231K22K
Mar 3, 2026Sell(S)359$321.58$115K22K
Mar 2, 2026Sell(S)100$328.71$33K24K
Mar 2, 2026Sell(S)329$327.67$108K24K
Mar 2, 2026Sell(S)392$326.81$128K24K
Mar 2, 2026Sell(S)258$325.63$84K25K
Mar 2, 2026Sell(S)90$324.65$29K25K
Mar 2, 2026Sell(S)47$323.62$15K25K
Mar 2, 2026Grant(A)4K$025K
Mar 2, 2026Sell(S)37$332.64$12K24K
Mar 2, 2026Sell(S)94$331.93$31K24K
Mar 2, 2026Sell(S)81$330.85$27K24K
Mar 2, 2026Sell(S)170$329.71$56K24K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Grant(A)8K$08K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001735276-26-000051) within minutes of acceptance. Every field above traces to the original document. Verify it directly: